Intact Therapeutics

Thermogel solution for the treatment of upper gastrointestinal bleeding (UGIB)


Industry: Medical

Country: USA


Upper gastrointestinal bleeding (UGIB) is a serious medical condition affecting millions of people worldwide. It can arise from various causes, such as peptic ulcers, esophageal varices, and gastric cancer. Notably, UGIB accounts for around 75% of all acute gastrointestinal bleeding cases. In the United States, it significantly contributes to morbidity and mortality, with a mortality rate of approximately 10%. To tackle this critical health concern, Intact Therapeutics is developing INT-201, a novel treatment for UGIB. This product utilizes a proprietary thermogel for drug delivery to the upper gastrointestinal tract, offering a unique approach to achieving hemostasis and stabilizing UGIB patients awaiting endoscopic treatment. The use of INT-201 is expected to lead to earlier stabilization, reduced need for blood transfusions, improved outcomes from endoscopy, and shorter hospital stays. 

This Small Business Innovation Research (SBIR) Phase II project aims to develop INT-201 for rapidly providing an initial blockade to upper gastrointestinal bleeding (UGIB) and stabilizing patients before endoscopy.